New Information Suggests Senior Pfizer Executives Conspired to Delay COVID-19 Vaccine Clinical Testing to Influence 2020 Election
On March 26, 2025, the Wall Street Journal reported that authorities were in possession of information that originated from a former senior Pfizer executive related to whether Pfizer "sat on the positive results of clinical trials" of its COVID-19 vaccine so as to influence the 2020 presidential election. The Journal identified Dr. Philip Dormitzer as the former Pfizer executive, and reported that he disclosed this information to his then-current employer, GSK plc, in "late 2024" following President Trump's election.
GSK stated:
"In November 2024, shortly after the election, Dr. Dormitzer approached a representative from the GSK human resources team to speak about a potential relocation abroad. As the human resources representative recalls, in their meeting, Dr. Dormitzer was visibly upset; he requested that he be relocated to Canada due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine. According to the human resources representative, when asked what prompted his request, Dr. Dormitzer made a comment to the effect of: 'Let's just say it wasn't a coincidence, the timing of the vaccine.'"
GSK further informed the Committee that Dr. Dormitzer had told GSK employees that "in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year."
judiciary.house.gov
Tom |
